AALL1631: International Phase 3 trial in Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) testing Imatinib in combination with two different cytotoxic chemotherapy backbones


NCT Number:



Study Status:






This phase 3 study is examining the best treatments for Philadelphia chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). The goal of this study is to see if using a less toxic chemotherapy regimen in combination with Imatinib can effectively treat standard risk Ph+ ALL. Patients with high risk Ph+ ALL will receive more intensive chemotherapy followed by stem cell transplant.

Are you Eligible? (Inclusion Criteria)

  • must be at least greater than 1 year and less than 21 years of age
  • Patients must be newly diagnosed
  • Patients must also meet all eligibility criteria as outlined in the study protocol

Specialty Area(s)

Leukemia, Childhood and Adolescent Cancers (Pediatric), Precision Oncology

Principal Investigator

Profile Headshot
  • Section Head of Oncology, Division of Hematology, Oncology, and Stem Cell Transplant

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032